Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified R-MINE vs R-GemOx in Late Relapsed DLBCL
NCT07389356Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Feb 2026
- Primary completion
- Oct 2027
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 2, randomised, open-label trial of mitoxantrone in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Complete response rate. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
mitoxantrone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07389356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07389356.